Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease

Area of Science:

• Biochemistry
• Cell Biology
• Neurology

Background:

• Dynamin 2 (DNM2) is a GTPase crucial for membrane fission.
• Mutations in DNM2 cause autosomal dominant centronuclear myopathy (ADCNM) and Charcot-Marie-Tooth neuropathy (CMT).
• DNM2 also modifies other CNM forms, with elevated levels observed in patients and models.

Purpose of the Study:

• To review the pathomechanisms of DNM2 mutations in centronuclear myopathy.
• To discuss therapeutic strategies targeting DNM2 hyperactivity in CNM.

Main Methods:

• Literature review of studies on Dynamin 2 (DNM2) function and mutations.
• Analysis of preclinical models and patient data related to CNM and DNM2.
• Synthesis of current research on therapeutic interventions for DNM2-related disorders.

Main Results:

• CNM-associated DNM2 mutations may lead to hyperactivity, while CMT mutations might impair lipid binding.
• Reduced DNM2 levels have reversed muscle phenotypes in preclinical CNM models.
• DNM2 is identified as a key factor in CNM pathogenesis.

Conclusions:

• DNM2 plays a critical role in skeletal muscle and CNM development.
• Targeting DNM2 hyperactivity presents a promising therapeutic avenue for CNM.
• Further research into DNM2's role could unlock new treatment strategies.